Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 1,799 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,799 shares of Insmed stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47. Following the completion of the sale, the insider now directly owns 84,797 shares in the company, valued at approximately $5,726,341.41. This represents a 2.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, May 15th, Martina M.D. Flammer sold 9,925 shares of Insmed stock. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total value of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total value of $570,146.48.

Insmed Price Performance

NASDAQ:INSM traded down $0.24 during mid-day trading on Monday, reaching $67.88. The stock had a trading volume of 1,334,593 shares, compared to its average volume of 2,325,724. The stock has a market capitalization of $12.36 billion, a P/E ratio of -12.14 and a beta of 0.84. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The firm has a 50 day moving average price of $71.57 and a two-hundred day moving average price of $73.16. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the business posted ($1.06) EPS. As a group, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on INSM. Morgan Stanley upped their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Bank of America boosted their target price on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Truist Financial lifted their price target on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Insmed in a report on Tuesday, February 25th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of INSM. Vanguard Group Inc. boosted its position in Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after buying an additional 49,149 shares during the period. Darwin Global Management Ltd. raised its position in Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after purchasing an additional 219,131 shares during the last quarter. Capital International Investors lifted its holdings in Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after buying an additional 593,206 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after acquiring an additional 273,759 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.